Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Monalizumab in Advanced Solid Tumors
NCT02671435Phase 2Active, not recruiting
- Sponsor
- MedImmune
- Start
- Feb 2016
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, open-label trial of monalizumab and durvalumab in solid tumor, colorectal cancer (CRC), ovarian cancer and 2 more (15 cohorts), sponsored by MedImmune. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events at 246.9 weeks, Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at 246.9 weeks and 8 more. Started Feb 2016; status: active, not recruiting.
02
Drugs
monalizumabdurvalumab
03
Conditions
solid tumorcolorectal cancer (CRC)ovarian cancerendometrial cancer (EC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02671435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671435.